Correlation between incidence of immune-related adverse events on atezolizumab and survival outcome
An exploratory pooled analysis based on three phase III studies on NSCLC suggests that immune-related adverse events to atezolizumab may indicate that the treatment is effective in that particular patient.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
